Interleukin Genetics moved closer to patent protection for its PerioPredict genetic risk test as the U.S. Patent and Trademark Office issued a notice of allowance for a patent.
A notice of allowance means the Patent and Trademark Office believes an invention qualifies for a patent, but the process is not yet complete. The company was granted a patent in New Zealand for the product in July 2015.
PerioPredict produces genetic data that can lower a patient's systemic inflammatory burden to reduce the risk of periodontitis and other chronic diseases, according to the company.
.RbyOLNR6ps.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.RbyOLNR6ps.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
